Finanzas de Vera Therapeutics, Inc (VERA)VERAVera Therapeutics, Inc

Evaluating the bottom line, Vera Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -91.75%, provide a clear picture of how effectively VERA converts its operational activities into shareholder value.

In the context of the broader market, VERA competes directly with industry leaders such as BCRX and ADRX. With a market capitalization of $2.02B, it holds a significant position in the sector. When comparing efficiency, VERA's gross margin of N/A stands against BCRX's 98.24% and ADRX's N/A. Such benchmarking helps identify whether Vera Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Vera Therapeutics has reported increasing losses, with a net income of -121 million expected for Q1 2026 and a forward P/E of 0, indicating no earnings expected in the near term. The company has a current ratio of 10.92, showing good liquidity, but the debt to equity ratio is at 18.45%, indicating moderate leverage.